VRTX

Business

Vertex Pharmaceuticals: A Deep Dive into Valuation After Recent Stock Pullback

Following a recent pullback, investors are scrutinizing whether Vertex Pharmaceuticals' (VRTX) current share price around $470 reflects its long-term cash flow potential. A discounted cash flow model suggests significant upside, while P/E ratios paint a more cautious picture, highlighting the complex valuation landscape for the biotech leader.

Business

Beyond the Magnificent Seven: Three Under-the-Radar Stocks With Legendary Potential

While market gains remain concentrated in a handful of tech giants, a disciplined focus on companies demonstrating sustained growth in sales, margins, and capital returns can uncover the next generation of multi-baggers. We examine three such contenders.

Business

February's Historical Underperformers: 25 S&P 500 Stocks to Watch Amid Seasonal Slump

As markets navigate a new month, historical data flags stocks with a persistent pattern of February weakness, with Biogen leading a list of notable underperformers compiled by Schaeffer's Investment Research.

Business

Therapeutics Sector Shows Resilience in Q3: United Therapeutics Lags as Halozyme and Biogen Outperform

A mixed third-quarter earnings season for therapeutics stocks reveals divergent paths, with United Therapeutics missing estimates while peers like Halozyme and Biogen post strong beats. Sector-wide revenue growth and positive stock reactions suggest underlying investor confidence despite regulatory and pricing headwinds.